# Andrew Siderowf

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrew-siderowf/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,673 |
| Field | Parkinson's Disease Mechanisms and Treatments |
| h-index | 84 |
| i10-index | 220 |
| Last Known Institution | University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5073135371 |
| ORCID iD | https://orcid.org/0000-0002-1750-7698 |
| Works | 363 |

## Researcher papers

- [Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030](https://scholariq.org/papers/projected-number-of-people-with-parkinson-disease-in-the-most-populous-nations/)
- [The Parkinson Progression Marker Initiative (PPMI)](https://scholariq.org/papers/the-parkinson-progression-marker-initiative-ppmi/)
- [Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study](https://scholariq.org/papers/assessment-of-heterogeneity-among-participants-in-the-parkinson-s-progression/)
- [The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort](https://scholariq.org/papers/the-parkinson-s-progression-markers-initiative-ppmi-establishing-a-pd-biomarker/)
- [A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research](https://scholariq.org/papers/a-biological-definition-of-neuronal-synuclein-disease-towards-an-integrated/)
- [A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease](https://scholariq.org/papers/a-randomized-clinical-trial-of-high-dosage-coenzyme-q10-in-early-parkinson/)
- [Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease](https://scholariq.org/papers/cognitive-performance-and-neuropsychiatric-symptoms-in-early-untreated-parkinson/)
- [Longitudinal study of normal cognition in Parkinson disease](https://scholariq.org/papers/longitudinal-study-of-normal-cognition-in-parkinson-disease/)
- [Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort](https://scholariq.org/papers/longitudinal-change-of-clinical-and-biological-measures-in-early-parkinson-s/)
- [Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression](https://scholariq.org/papers/validation-of-serum-neurofilament-light-chain-as-a-biomarker-of-parkinson-s/)
- [Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study](https://scholariq.org/papers/clinical-and-dopamine-transporter-imaging-characteristics-of-non-manifest-lrrk2/)

## Researcher topics

- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Neurological disorders and treatments](https://scholariq.org/topics/neurological-disorders-and-treatments/)
- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.